Company Filing History:
Years Active: 2016
Title: Zhewei Tang: Innovator in Antibody Engineering
Introduction
Zhewei Tang is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of antibody engineering, particularly in the development of therapeutic agents targeting mesothelin-expressing tumors. His innovative work has the potential to impact cancer treatment significantly.
Latest Patents
Zhewei Tang holds a patent titled "Mesothelin antibodies and methods for eliciting potent antitumor activity." This patent describes the use of phage display antibody engineering technology and synthetic peptide screening to identify two human single-domain antibodies, SD1 and SD2, that target mesothelin. SD1 recognizes a conformational epitope at the C-terminal end of human mesothelin, while SD2 binds to full-length mesothelin. The SD1-hFc fusion protein, derived from SD1, exhibits strong complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity against mesothelin-expressing tumor cells. Furthermore, it has shown significant tumor growth inhibition in xenograft models.
Career Highlights
Zhewei Tang is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research in antibody development and cancer therapeutics.
Collaborations
Zhewei Tang has collaborated with notable colleagues, including Mitchell Ho and Ira H Pastan. Their combined expertise has contributed to advancements in the understanding and treatment of cancer.
Conclusion
Zhewei Tang's innovative work in antibody engineering and his patent on mesothelin-targeting antibodies highlight his significant contributions to cancer research. His efforts may pave the way for new therapeutic strategies in oncology.